Physician profile
Vidya Sagar
NPI 1457376683
$12,056.63
in general payments reported to CMS, 2019-2025
27 companies · $1,679 in 2025
The $1,679 reported for 2025 was more than what 88% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,104 · 2020: $2,346 · 2021: $978 · 2022: $2,220 · 2023: $1,547 · 2024: $2,182 · 2025: $1,679.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,184 · Consulting Fee: $150 · Education: $74.19.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,183.91 |
| Consulting Fee | $150.00 |
| Education | $74.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $2,074.27 | 2019-2023 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $2,039.48 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $946.40 | 2019-2025 | Krystexxa, Tavneos |
| Travere Therapeutics, INC. | $904.89 | 2022-2025 | Filspari |
| Bayer Healthcare Pharmaceuticals INC. | $735.93 | 2021-2025 | |
| Novo Nordisk INC | $717.26 | 2021-2025 | Ozempic, Rybelsus |
| Mallinckrodt Hospital Products INC. | $670.44 | 2020-2025 | Acthar, Terlivaz |
| Lilly USA, LLC | $627.90 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Opko Pharmaceuticals, LLC | $527.02 | 2019-2025 | Rayaldee |
| Otsuka America Pharmaceutical, INC. | $448.77 | 2019-2025 | Jynarque, Voyxact |
| Fresenius USA Marketing, INC. | $448.32 | 2019-2025 | Velphoro, Korsuva, Velphoro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $358.15 | 2023-2025 | Jardiance |
| Calliditas Therapeutics US INC. | $305.44 | 2022-2025 | Tarpeyo |
| Glaxosmithkline, LLC. | $244.09 | 2022-2025 | Benlysta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $206.88 | 2021-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $205.59 | 2022-2024 | Lupkynis |
| Akebia Therapeutics INC | $181.17 | 2019-2024 | Vafseo, Auryxia |
| Ardelyx, INC. | $90.89 | 2023-2025 | Ibsrela |
| Mallinckrodt Enterprises LLC | $74.31 | 2019 | |
| Nuwellis, INC. | $61.25 | 2019-2025 | Aquadex Smartflow Console |
| Cormedix INC. | $37.54 | 2024-2025 | Defencath, Defencath |
| Ultragenyx Pharmaceutical INC. | $33.29 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.76 | 2021 | |
| Vifor Pharma, INC. | $29.29 | 2019-2020 | |
| Kyowa Kirin, INC. | $22.90 | 2025 | |
| Alnylam Pharmaceuticals INC. | $19.57 | 2023 | Givlaari |
| Takeda Pharmaceuticals U.S.A., INC. | $15.83 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vidya Sagar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.